A Comprehensive Pillar Resource for Researchers
Retatrutide (LY3437943) represents one of the most significant advances in metabolic peptide research of the past decade. As a first-in-class triple hormone receptor agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, it has produced some of the highest average weight reductions ever recorded in late-stage clinical trials.
This guide synthesizes the published Phase 2 data, the full TRIUMPH Phase 3 program results available as of mid-2026, mechanistic insights, safety observations, and ongoing research directions. It is written for researchers, clinicians following the literature, and those studying multi-receptor peptide pharmacology.
1. What Is Retatrutide?
Retatrutide is a synthetic, once-weekly peptide developed by Eli Lilly. It is a single molecule engineered to activate three distinct Class B G-protein-coupled receptors simultaneously:
- GIP receptor (GIPR)
- GLP-1 receptor (GLP-1R)
- Glucagon receptor (GCGR)
Structural features include a peptide backbone derived primarily from GIP with modifications that introduce GLP-1 and glucagon activity, plus a C20 fatty diacid moiety that enables albumin binding and extends half-life to support weekly dosing.
Unlike dual agonists such as tirzepatide (GIP + GLP-1), retatrutide adds calibrated glucagon receptor agonism. This third pathway is believed to increase energy expenditure and hepatic fat oxidation while the concurrent GIP and GLP-1 activity helps maintain glycemic balance.
Key Identifiers
- Developmental code: LY3437943
- CAS Number: 2381089-83-2
- Approximate molecular weight: ~4,731 Da
- Administration (clinical trials): Once-weekly subcutaneous injection
Retatrutide remains an investigational compound. It is not FDA-approved as of August 2026. Lilly has indicated plans to submit a Biologics License Application (BLA) in Q1 2027.
2. Mechanism of Action
Retatrutide’s design reflects a deliberate potency hierarchy observed in preclinical characterization: highest relative activity at the GIP receptor, moderate activity at the GLP-1 receptor, and carefully calibrated activity at the glucagon receptor.
| Receptor | Primary Effects Relevant to Metabolic Research | Contribution in Retatrutide |
|---|---|---|
| GIPR | Glucose-dependent insulin secretion, adipose tissue lipid buffering, potential effects on bone and CNS | Highest relative potency; supports lipid handling and insulinotropic activity |
| GLP-1R | Appetite suppression, delayed gastric emptying, glucose-dependent insulin release, glucagon suppression | Core satiety and glycemic control component |
| GCGR | Increased energy expenditure, hepatic fatty acid oxidation, thermogenesis | Differentiating feature vs dual agonists; intended to raise energy expenditure without unopposed hyperglycemia |
The concurrent activation of all three pathways allows researchers to study both reduced energy intake (primarily GLP-1/GIP-mediated) and increased energy expenditure (glucagon-mediated) within a single molecular tool. Preclinical and early clinical data suggest the insulinotropic effects of GIP and GLP-1 help counterbalance the gluconeogenic potential of glucagon receptor activation.
Primary literature on the engineering and receptor pharmacology includes Coskun et al. (Cell Metabolism, 2022) and subsequent structural studies.
3. Clinical Development Timeline
| Phase / Milestone | Key Details | Year / Status |
|---|---|---|
| First-in-human / Phase 1 | Dose-finding and safety in healthy volunteers and T2D | 2019–2021 |
| Phase 2 Obesity Trial | n=338; up to 24.2% weight loss at 48 weeks | Published NEJM 2023 |
| TRIUMPH Phase 3 Program Launch | Multiple registrational trials | 2023 onward |
| TRIUMPH-4 (OA + Obesity) | First Phase 3 readout; 28.7% weight loss + pain reduction | Dec 2025 |
| TRIUMPH-1 (Pivotal Obesity) | 28.3% at 80 weeks (12 mg); extension data to 104 weeks | May 2026 |
| TRIUMPH-2 (Obesity + T2D) | Up to 20.8% at 80 weeks + A1C reductions | July 2026 |
| TRIUMPH-3 (Severe Obesity + CVD) | Up to 22.6% at 80 weeks | July 2026 |
| Planned BLA Submission | — | Q1 2027 (Lilly guidance) |
The TRIUMPH program uses a basket-trial design that efficiently evaluates weight management alongside related conditions (obstructive sleep apnea, knee osteoarthritis, and cardiovascular disease).
4. Key Clinical Trial Results
Phase 2 Obesity Trial (NEJM 2023)
Jastreboff et al., N Engl J Med 2023;389:514-526. ClinicalTrials.gov: NCT04881760
| Dose | Mean Weight Change at 48 Weeks | ≥15% Weight Loss |
|---|---|---|
| Placebo | −2.1% | 2% |
| 1 mg | −8.7% | — |
| 4 mg | −17.1% | 60% |
| 8 mg | −22.8% | 75% |
| 12 mg | −24.2% | 83% |
Weight loss had not fully plateaued at 48 weeks in the higher-dose arms, motivating longer Phase 3 studies.
TRIUMPH-1 – Pivotal Obesity Trial (No Diabetes)
Topline results May 2026 (n≈2,339). Primary endpoint at 80 weeks.
| Dose | Mean Weight Loss (80 weeks) | Absolute Loss (approx.) | ≥30% Weight Loss |
|---|---|---|---|
| 4 mg | 19.0% | 47.2 lbs | — |
| 9 mg | 25.9% | 64.4 lbs | — |
| 12 mg | 28.3% | 70.3 lbs | 45.3% |
| Placebo | 2.2% | 5.5 lbs | — |
In a pre-specified extension among participants with baseline BMI ≥35 who continued 12 mg, mean loss reached 30.3% (≈85 lbs) at 104 weeks.
TRIUMPH-2 – Obesity or Overweight + Type 2 Diabetes
Topline July 2026 (n=1,152). 80-week results.
| Dose | Mean Weight Loss | Absolute Loss | A1C Reduction (max) |
|---|---|---|---|
| 4 mg | 12.7% | 29.8 lbs | — |
| 9 mg | 19.1% | 45.4 lbs | — |
| 12 mg | 20.8% | 49.6 lbs | up to 1.6% |
| Placebo | 4.0% | 9.3 lbs | 0.2% |
TRIUMPH-3 – Severe Obesity + Established Cardiovascular Disease
Topline July 2026 (n≈1,949). 80-week results.
| Dose | Mean Weight Loss | Absolute Loss |
|---|---|---|
| 9 mg | 21.6% | 52.7 lbs |
| 12 mg | 22.6% | 55.8 lbs |
| Placebo | 3.2% | 7.7 lbs |
Additional cardiometabolic improvements at 12 mg included:
- Triglycerides −37%
- Non-HDL cholesterol −16.5%
- Systolic blood pressure −9.3 mmHg
- Waist circumference −19.0 cm
- hsCRP −51.2%
MACE (major adverse cardiovascular events) occurred less frequently than anticipated in both arms; the hazard ratio for MACE-5 was 0.82 (95% CI 0.55–1.22), which did not reach statistical significance for superiority in this trial.
TRIUMPH-4 – Obesity + Knee Osteoarthritis
First Phase 3 readout (December 2025). At 68 weeks, 12 mg produced 28.7% mean weight loss and substantial reductions in WOMAC pain scores (up to ~75% reduction in some analyses).
5. Comparison with Existing Agents
| Agent | Receptor Targets | Highest Reported Mean Weight Loss (Approx.) | Key Differentiator |
|---|---|---|---|
| Semaglutide 2.4 mg | GLP-1 | ~15–17% (STEP trials) | Established CV outcome data |
| Tirzepatide 15 mg | GIP + GLP-1 | ~21–22.5% (SURMOUNT) | Dual agonist; strong glycemic data |
| Retatrutide 12 mg | GIP + GLP-1 + Glucagon | 28.3% (TRIUMPH-1, 80 wk) | Triple agonist; energy expenditure component |
Retatrutide’s results in the non-diabetic obesity population (TRIUMPH-1) currently stand as the highest average weight reductions reported for any investigational or approved once-weekly peptide in large Phase 3 trials.
6. Safety and Tolerability Profile
Across the Phase 2 and Phase 3 program, the most common adverse events have been gastrointestinal (nausea, vomiting, diarrhea, constipation), consistent with the incretin class. These events were generally dose-dependent, mostly mild-to-moderate, and partially mitigated by slower dose escalation.
Discontinuation rates due to adverse events in recent TRIUMPH trials ranged approximately 4–12% depending on dose and population, compared with ~5% on placebo in some arms.
Other observations include transient increases in heart rate (also seen with other agents in the class) that tended to peak and then decline. Long-term cardiovascular outcome data continue to be collected in dedicated trials (e.g., TRIUMPH-Outcomes).
Researchers should note that retatrutide remains investigational. All clinical use is restricted to controlled trials.
7. Research Applications and Scientific Interest
For laboratory and preclinical investigators, retatrutide offers a unique tool for studying:
- Simultaneous energy intake suppression and energy expenditure elevation
- Multi-receptor pharmacology and receptor crosstalk
- Effects on hepatic steatosis / MASLD models
- Comparative mono-, dual-, and triple-agonist mechanisms
- Albumin-binding and long-acting peptide design strategies
- Cardiometabolic risk factor modulation beyond weight alone
The molecule’s balanced triple agonism makes it particularly valuable for dissecting the relative contributions of GIP, GLP-1, and glucagon pathways in controlled experimental systems.
Important: Research-grade material, when available from qualified suppliers, is supplied strictly for laboratory and preclinical research use only and is not intended for human or veterinary use.
8. Ongoing and Future Trials
As of mid-2026, multiple additional studies remain active or planned, including:
- Direct comparison trials versus tirzepatide
- Maintenance of weight reduction studies
- Trials in chronic kidney disease, MASLD/MASH, and additional obesity subpopulations
- Long-term cardiovascular and kidney outcomes (TRIUMPH-Outcomes)
These will further clarify durability, comparative efficacy, and organ-specific benefits.
9. Key Scientific References
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526. NEJM Link
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist… Cell Metabolism. 2022.
- Eli Lilly TRIUMPH-1 topline results (May 2026) and TRIUMPH-2 / TRIUMPH-3 topline results (July 2026) — official press releases available on investor.lilly.com.
- ClinicalTrials.gov entries: NCT04881760 (Phase 2), NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT05882045 (TRIUMPH-3), NCT05931367 (TRIUMPH-4).
- Additional structural and receptor pharmacology papers published 2024–2026 examining cAMP signaling and receptor dynamics.
10. Frequently Asked Questions
Is retatrutide approved? No. It remains investigational. Lilly has guided toward a potential BLA submission in Q1 2027.
How does the glucagon component affect blood glucose? Clinical data to date show net improvements in glycemic control in both non-diabetic and type 2 diabetes populations, suggesting the insulinotropic effects of GIP/GLP-1 predominate at the doses studied.
What makes retatrutide different from tirzepatide? The addition of glucagon receptor agonism, intended to increase energy expenditure beyond what dual GIP/GLP-1 agonism achieves.
Where can researchers find the primary data? The 2023 Phase 2 paper is fully published in the New England Journal of Medicine. Phase 3 detailed publications are expected in peer-reviewed journals following the 2026 topline announcements.
Conclusion
Retatrutide has advanced the frontier of multi-receptor metabolic peptide research. With Phase 3 data demonstrating average weight reductions in the 20–28% range (and higher in selected extensions), it has set a new benchmark for pharmacological approaches to obesity and related metabolic conditions.
For the research community, it provides a powerful experimental tool for probing the integrated effects of GIP, GLP-1, and glucagon signaling. As additional peer-reviewed publications and longer-term outcome data emerge, the scientific understanding of this triple-agonist class will continue to deepen.
Research Use Only Notice All discussion of retatrutide in non-clinical contexts refers to its status as an investigational research compound. Materials supplied for laboratory research are intended strictly for qualified scientific investigation and are not for human consumption, therapeutic use, or any clinical application.
This guide is intended as a living resource. As full peer-reviewed Phase 3 manuscripts and additional trial readouts become available, key sections can be updated. Researchers are encouraged to consult the primary literature and ClinicalTrials.gov for the most current protocol details.
Related articles
Retatrutide and Metabolic Flexibility
Retatrutide vs CagriSema
Retatrutide Clinical Trials
Best Place to Buy Retatrutide
Retatrutide Half-Life
Retatrutide Side Effects
How Does Retatrutide Work?
Retatrutide vs. Ozempic: Is Retatrutide Ozempic?
Retatrutide 60mg price
Where Can I Buy Retatrutide?
Retatrutide vs Tirzepatide vs Semaglutide
Potential Kidney and Liver Benefits from Retatrutide
Retatrutide vs Tirzepatide: Why Researchers Are Paying Attention to Next-Generation GLP-1 Peptides
Retatrutide Cardiovascular Trial Explained: What Researchers Are Studying
Retatrutide Research Guide | Understanding GLP-1, GIP, and Glucagon Agonists
Retatrutide Phase 3 Results: What Eli Lilly’s TRIUMPH-4 Trial Means for the Future of Obesity Treatment and the Peptide Industry
Retatrutide Cardiovascular Trial Explained: What Researchers Are Studying
Retatrutide Peptide 20mg (RUO) | ≥99% Purity | Research Grade | 20mg
Retatrutide vs. Cagrilintide: What’s the Difference? A Complete Research Guide
PRoduct Pages
Retatrutide Peptide 20mg (RUO) | ≥99% Purity | Research Grade | 20mg
Retatrutide Peptide 60mg (RUO) | ≥99% Purity | Research Grade | 60mg
Retatrutide Peptide 10mg (RUO) | ≥99% Purity | Research Grade | 10mg
